Monitor for actual sales activity under this ATM program, as continuous equity issuance could pressure the stock price, especially given the company's $95M market cap. The lack of disclosed use of proceeds increases uncertainty around capital efficiency.
QTTB drugs
QTTB drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $5.47entry
- T+1 · 7mo ago +4.57%α +5.06% · $5.72
- T+5 · 7mo ago −7.86%α −8.26% · $5.04
- T+20 · 6mo ago +29.62%α +24.66% · $7.09
- T+60 · 4mo ago +175.69%α +170.91% · $15.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Q32 Bio Inc. has filed an additional prospectus supplement to raise up to $75 million through its at-the-market (ATM) offering program with Cantor Fitzgerald, following the full utilization of a prior $14.2 million ATM offering. This new shelf capacity provides continued access to equity funding for the clinical-stage biotech.
Key Facts
- Q32 Bio has fully drawn down a prior $14.2 million ATM offering with Cantor Fitzgerald
- Filed a new prospectus supplement to offer up to $75 million in common stock via the same ATM program
- The offering is under a shelf registration (Form S-3) declared effective April 21, 2025
- No specific use of proceeds or pricing details disclosed in this filing
Financial Impact
$75 million in potential equity dilution
Risk Factors
- Significant shareholder dilution from potential $75M in new share issuance
- Downward pressure on stock price due to overhang from ATM program
- Lack of transparency on use of proceeds raises capital allocation concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-177178 |
| Document: d31430dex51.htm | 0001193125-26-177178 |
| Document: 0001193125-26-177178-index-headers.html | 0001193125-26-177178 |
| Document: 0001193125-26-177178-index.html | 0001193125-26-177178 |
| Document: 0001193125-26-177178.txt | 0001193125-26-177178 |
Track record
23 reports on QTTB
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +48.47% at T+60 after the Jul 14, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $8.29 Now $8.29 −0.00% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.47 Now $8.29 −2.13% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $8.71 Now $8.29 −4.82% settles Dec 15
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $8.97 Now $8.29 −7.58% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $9.06 Now $8.29 −8.50% settles Nov 25
- Oct 9, 20265w ago SC 13G Neutral 4/10 Entry $8.74 to $9.36 Now $8.29 −5.15% ▲ +7.09% +10.36% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $8.27 to $8.71 Now $8.29 +0.24% ▲ +5.32% +4.05% vs SPY
- Sep 14, 20269w ago 8-K Neutral 3/10 Entry $10.91 to $8.74 Now $8.29 −24.01% ▼ −19.89% −22.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers